A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection

Trial Profile

A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs PRO 140 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors CytoDyn
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 05 Oct 2016 Status changed from recruiting to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top